Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095801 | 0.79 | SSTR4 (0.39) | MAPTPKM | |
| SCHEMBL4080649 | 0.78 | TRPM8 (0.46) | TRPM8HSD17B2HTR2CFFAR1MAPT | |
| SCHEMBL1096138 | 0.76 | TRPM8 (0.42) | TRPM8HSD17B2HTR2CFFAR1MAPT | |
| SCHEMBL1096263 | 0.71 | SSTR4 (0.39) | MAPTPKM | |
| SCHEMBL16274995 | 0.69 | SSTR4 (0.42) | — | |
| SCHEMBL5158470 | 0.67 | MAPT (0.43) | HSD17B2MAPTPKM | |
| Trifluoroacetic Acid SCHEMBL30149807 | 0.65 | OPRD1 (0.47) | HTR2CPOLB | |
| SCHEMBL14382757 | 0.65 | HTR2C (0.55) | HTR2CMAPTPKM | |
| SCHEMBL17474525 | 0.65 | HTR2C (0.55) | HTR2CMAPTPKMREN | |
| SCHEMBL14256161 | 0.64 | REN (0.60) | HTR2CREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | CASR, CYP2R1, HCAR1 | TRPM8 145/4885HSD17B2 1097/4885HTR2C 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.